Sorafenib (brand name Nexavar) / mTOR Cancer Research Results

SRF, Sorafenib (brand name Nexavar): Click to Expand ⟱

Features: kinase inhibitor drug

Sorafenib (brand: Nexavar) — an oral multikinase inhibitor targeting RAF kinases and multiple receptor tyrosine kinases (VEGFR-1/2/3, PDGFR-β, FLT3, KIT, RET). Approved for advanced hepatocellular carcinoma (HCC), renal cell carcinoma (RCC), and differentiated thyroid carcinoma (DTC).

Primary mechanisms (conceptual rank):
1) RAF (CRAF/BRAF) inhibition → ↓ MAPK/ERK signaling
2) VEGFR/PDGFR blockade → anti-angiogenesis
3) Induction of mitochondrial apoptosis (Mcl-1↓; caspases↑)
4) Metabolic/redox stress modulation (ROS shifts; ferroptosis sensitization reported)
5) Tumor microenvironment effects (vascular normalization / hypoxia interplay)

Bioavailability / PK relevance: Oral; variable absorption; highly protein-bound; metabolized mainly by CYP3A4 and UGT1A9; half-life ~25–48 h. Achievable plasma levels are within low-micromolar range.

In-vitro vs oral exposure: Many mechanistic studies use concentrations within or slightly above clinical plasma range; off-target cytotoxicity typically at higher doses.

Clinical evidence status: FDA-approved for HCC, RCC, DTC; established survival benefit in advanced disease (modest median OS improvement).

Inhibitors of vascular endothelial growth factor receptor (VEGFR); used to treat kidney, liver and thyroid cancers.

Sorafenib (Nexavar) — Cancer vs Normal Cell Pathway Map

Rank	Pathway / Axis	Cancer Cells	Normal Cells	TSF	Primary Effect	Notes / Interpretation
1	RAF → MEK → ERK (MAPK)	↓ (primary)	↔ / ↓ (proliferating cells)	R/G	Reduced proliferative signaling	Core intracellular target; inhibits CRAF and wild-type BRAF (not selective for BRAF V600E like vemurafenib).
2	VEGFR / PDGFR (angiogenesis)	↓ tumor vascularization	↓ endothelial proliferation	R/G	Anti-angiogenic effect	Major driver of clinical efficacy in HCC/RCC; affects tumor microenvironment.
3	Intrinsic apoptosis (Mcl-1↓, caspases↑)	↑	↔ / ↑ (dose-dependent)	R/G	Mitochondrial apoptosis	Mcl-1 downregulation is characteristic; enhances chemosensitivity in some models.
4	ROS	↑ (dose-dependent)	↔ / ↑ (high exposure)	P/R	Oxidative stress contribution	Redox stress may contribute to cytotoxicity and resistance mechanisms.
5	Ferroptosis	↑ (context-dependent)	↔	R/G	Lipid peroxidation vulnerability	Reported to sensitize HCC cells to ferroptosis via system Xc⁻ / SLC7A11 modulation.
6	PI3K/AKT/mTOR	↓ (secondary; model-dependent)	↔	R/G	Reduced survival signaling	Often compensatory pathway in resistance; combination target in trials.
7	HIF-1α	↓ (anti-angiogenic coupling)	↔	G	Reduced hypoxia signaling	Indirect via vascular effects; hypoxia may paradoxically increase in resistant tumors.
8	NRF2	↑ (resistance-associated; context-dependent)	↔	R/G	Adaptive antioxidant response	NRF2 upregulation linked to sorafenib resistance in HCC.
9	Ca²⁺ signaling	↔ (stress-related)	↔	P/R	Not primary axis	Secondary to mitochondrial stress; not direct target.
10	Clinical Translation Constraint	↓ (constraint)	↓ (toxicity)	—	Resistance + tolerability limits	Common AEs: hand-foot skin reaction, hypertension, diarrhea; resistance frequent via MAPK reactivation or NRF2 upshift.

TSF legend:
P: 0–30 min (kinase inhibition onset)
R: 30 min–3 hr (signaling cascade suppression)
G: >3 hr (gene regulation, angiogenesis suppression, apoptosis)

mTOR, mammalian target of rapamycin: Click to Expand ⟱

Source: HalifaxProj (inhibit)

Type:

mTOR (mechanistic target of rapamycin) is a central regulator of cell growth, proliferation, metabolism, and survival. It is a serine/threonine kinase that integrates signals from nutrients, growth factors, and cellular energy status.
mTOR promotes protein synthesis and cell growth by activating downstream targets such as S6 kinase and 4E-BP1. In cancer, this pathway can become hyperactivated, leading to uncontrolled cell proliferation.

mTor Inhibitors:
-rapamycin (Sirolimus): classic natural product mTOR inhibitor
-Curcumin
-Resveratrol
-Epigallocatechin Gallate (EGCG)
-Honokiol

Scientific Papers found: Click to Expand⟱

1168-

IVM,

SRF,

Ivermectin synergizes sorafenib in hepatocellular carcinoma via targeting multiple oncogenic pathways

in-vitro,

HCC,

TumMeta↓, mTOR↓, EMT↓, CSCsMark↓, STAT3↓,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:

Proliferation, Differentiation & Cell State ⓘ

CSCsMark↓, 1, EMT↓, 1, mTOR↓, 1, STAT3↓, 1,

Migration ⓘ

TumMeta↓, 1,
Total Targets: 5

Pathway results for Effect on Normal Cells:

Total Targets: 0

Scientific Paper Hit Count for: mTOR, mammalian target of rapamycin

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells